Filing Flows › Health Care › Integer Holdings (ITGR)
Integer Holdings (ITGR) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 29, 2026 · Integer Holdings (ITGR) Q3 2026 earnings results →
Q3 2026 Revenue down 4% year over year to $450M · 3¢ of every $1 of revenue kept as net profit · operating margin 6.3%
Integer Holdings made $450M in Q3 2026 (-4% Y/Y): Cardio & Vascular $263M, Cardiac Rhythm Management & Neuromodulation $176M, Other Markets $10.8M. Operating margin 6.3%, net earnings $15.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 29, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $449.7M in Q3 2026, down 4% year over year and down 3% from the previous quarter. Cardio & Vascular was the largest line at 59% of revenue. Cardio & Vascular lost $14.1M year over year (down 5%), 78% of the total change.
Gross margin was 22.6%, down 4.4 points from Q3 2025. Operating profit was $28.2M, a 6.3% margin (down 5.8 points year over year). Operating expenses grew 5% against a revenue fall of 4%. The fastest-growing cost line was Research & development (+24%). Net earnings were $15.0M, down 62% year over year. The effective tax rate was 14.5%.
Operating cash flow was $36.6M (down 44% year over year), 245% of net earnings. Non-cash charges added back $34.4M of depreciation and amortization and $5.2M of share-based compensation. Working capital and other items used $17.9M. Capital expenditures of $20.5M left free cash flow of $16.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 29, 2026 | $450M | -4% | 6.3% | $15.0M | $36.6M |
| Q2 2026 | 10-Q | Aug 4, 2026 | $464M | -3% | 7.4% | $23.6M | $59.7M |
| Q1 2026 | 10-Q | Apr 30, 2026 | $440M | +0.5% | 7.2% | $16.5M | $24.7M |
| Q4 2025 | 10-K | Feb 23, 2026 | $472M | +5% | 11.8% | $48.6M | $55.4M |
| Q3 2025 | 10-Q | Oct 23, 2025 | $468M | +8% | 12.1% | $39.7M | $65.6M |
| Q2 2025 | 10-Q | Jul 24, 2025 | $476M | +11% | 12.5% | $37.0M | $43.9M |
| Q1 2025 | 10-Q | Apr 24, 2025 | $437M | +7% | 11.3% | −$22.5M | $31.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- BSX — 49% of its revenue · Stated in 10-K (sentence) · source
- ABT — 10% of its revenue · Stated in 10-K (sentence) · source
About Integer Holdings
Integer Holdings Corporation, headquartered in Plano, Texas, is one of the world’s largest medical device contract development and manufacturing organizations (“CDMOs”), serving the Cardio and Vascular, Neuromodulation, and Cardiac Rhythm Management markets. As a strategic partner of choice, we advance the goals of our medical device customers through industry-leading engineering and manufacturing, with a relentless commitment to quality, service, and innovation. Our brands include Greatbatch Medical ® and Lake Region Medical ® . Our primary customers include large, multi-national original equipment manufacturers (“OEMs”) and their affiliated subsidiaries. When used in this report, the terms “Integer,” “we,” “us,” “our” and the “Company” mean Integer Holdings Corporation and its subsidiaries.
In its own words, from its 10-K, filed Feb 23, 2026.
Integer Holdings against its Electromedical & Electrotherapeutic Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -4% against the peers' median +14%. Operating margin: 6.3% against the peers' median 6.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ITGR Integer Holdings | Q3 2026 | $450M | -4% | 6.3% |
| MDT Medtronic | Q1 FY27 | $9.8B | +14% | 18.1% |
| LIVN LivaNova | Q3 2026 | $393M | +10% | 7.2% |
| CNMD Conmed | Q3 2026 | $336M | -0.7% | 11.1% |
| TMDX TransMedics Group | Q3 2026 | $203M | +41% | 13.9% |
| AXGN Axogen | Q3 2026 | $75.8M | +26% | 1.3% |
| OM Outset Medical | Q3 2026 | $33.6M | +14% | -36.5% |
| CBLL Ceribell | Q3 2026 | $29.3M | +30% | -70.0% |
| BLFS Biolife Solutions | Q2 2026 | $28.5M | +22% | 6.0% |
Source: Integer Holdings 10-Q on SEC EDGAR · CIK 1114483 · Electromedical & Electrotherapeutic Apparatus
13F: who owns ITGR and who is buying
More on ITGR
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Integer Holdings gross margin by quarter
- Integer Holdings operating margin by quarter
- Integer Holdings net income by quarter
- Integer Holdings free cash flow by quarter
- Integer Holdings R&D spending by quarter
- Integer Holdings capital expenditures by quarter
- Integer Holdings Cardio & Vascular revenue by quarter
- Integer Holdings Cardiac Rhythm Management & Neuromodulation revenue by quarter
- Integer Holdings Other Markets revenue by quarter